01 8月 2019 by admin in UncategorizedComments Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
25 7月 2019 by admin in UncategorizedComments Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
23 7月 2019 by admin in UncategorizedComments resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
23 7月 2019 by admin in UncategorizedComments Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda
05 6月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
31 5月 2019 by admin in UncategorizedComments Crescendo Biologics Announces Prestigious Academic Research Collaborations
28 5月 2019 by admin in UncategorizedComments Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
24 5月 2019 by admin in UncategorizedComments Crescendo Biologics Achieves Another Milestone in its Strategic Collaboration with Takeda
19 5月 2019 by admin in UncategorizedComments Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals
16 5月 2019 by admin in UncategorizedComments TEMPEST THERAPEUTICS STARTS PHASE I/IB CLINICAL TRIAL WITH FIRST-IN-CLASS PPAR ALPHA ANTAGONIST
